MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

161.86 -4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

160.63

Max

170.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

18M

45M

Verkäufe

7.3M

91M

KGV

Branchendurchschnitt

56.116

59.668

EPS

1.53

Gewinnspanne

49.901

Angestellte

275

EBITDA

12M

43M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+29.41% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-194M

4.9B

Vorheriger Eröffnungskurs

165.86

Vorheriger Schlusskurs

161.86

Nachrichtenstimmung

By Acuity

50%

50%

144 / 385 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Apr. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

21. Apr. 2025, 22:37 UTC

Akquisitionen, Fusionen, Übernahmen

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

21. Apr. 2025, 23:58 UTC

Market Talk

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

21. Apr. 2025, 23:46 UTC

Market Talk

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

21. Apr. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

21. Apr. 2025, 23:43 UTC

Market Talk

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

21. Apr. 2025, 23:22 UTC

Akquisitionen, Fusionen, Übernahmen

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

21. Apr. 2025, 23:22 UTC

Akquisitionen, Fusionen, Übernahmen

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

21. Apr. 2025, 22:35 UTC

Top News

Harvard Is Suing the Trump Administration -- 2nd Update

21. Apr. 2025, 22:02 UTC

Top News

Harvard Is Suing the Trump Administration -- Update

21. Apr. 2025, 21:46 UTC

Top News

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

21. Apr. 2025, 21:03 UTC

Top News

Harvard Is Suing the Trump Administration -- WSJ

21. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

21. Apr. 2025, 20:28 UTC

Top News

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

21. Apr. 2025, 20:24 UTC

Top News

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

21. Apr. 2025, 19:14 UTC

Market Talk

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

21. Apr. 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

21. Apr. 2025, 19:07 UTC

Top News

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

21. Apr. 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Apr. 2025, 18:44 UTC

Market Talk

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

21. Apr. 2025, 18:28 UTC

Market Talk

Gold Finishes at New Record as Equities Slide -- Market Talk

21. Apr. 2025, 18:26 UTC

Top News

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

21. Apr. 2025, 16:27 UTC

Market Talk

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

21. Apr. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

21. Apr. 2025, 16:16 UTC

Top News

Dow and Dollar Drop on Jitters Over Fed and Trade -- WSJ

21. Apr. 2025, 16:00 UTC

Market Talk

Crocs Could Double Some Prices as Tariffs Threaten Heydude Line -- Market Talk

21. Apr. 2025, 15:53 UTC

Ergebnisse

Canadian Telcos Need to Show Pricing Discipline as Subscriber Growth Faces Challenges -- Analysis

21. Apr. 2025, 15:51 UTC

Market Talk

Stock Market Losses Keep Pressure On Oil Prices -- Market Talk

21. Apr. 2025, 15:49 UTC

Market Talk

Capital Plans, M&A in Focus When Precious Metals Miners Report -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

29.41% Vorteil

12-Monats-Prognose

Durchschnitt 218.14 USD  29.41%

Hoch 245 USD

Tief 200 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

7

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

158.7752 / 169.12Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

144 / 385 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.